<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03545711</url>
  </required_header>
  <id_info>
    <org_study_id>NCC201803012</org_study_id>
    <nct_id>NCT03545711</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer</brief_title>
  <official_title>Safety and Efficacy of Irinotecan Combined With Anlotinib in Patients With Pretreated Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with pretreated advanced colorectal cancer are recruited to the phase I portion of&#xD;
      this prospective non-randomised study in an escalated dose cohort. The primary endpoint of&#xD;
      the dose-escalation phase is to determine the maximum tolerated dose (MTD) and recommended&#xD;
      phase 2 dose (RP2D) of anlotinib when given in combination with irinotecan. The phase II&#xD;
      (dose-expansion) portion is designed to characterize the safety and potential efficacy of the&#xD;
      combination therapy in pretreated advanced colorectal cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 26, 2018</start_date>
  <completion_date type="Anticipated">November 24, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>6 months</time_frame>
    <description>the maximum tolerated dose (MTD) of Anlotinib when administered in combination with fixed dose of irinotecan in advanced colorectal cancer patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>18 months</time_frame>
    <description>the overall response rate (ORR) of Anlotinib when administered in combination with fixed dose of irinotecan in advanced colorectal cancer patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>18 months</time_frame>
    <description>the disease control rate (DCR) of the combination of Anlotinib with Irinotecan in pretreated advanced colorectal cancer patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>18 months</time_frame>
    <description>the progression free survival (PFS) of the combination of Anlotinib with Irinotecan in pretreated advanced colorectal cancer patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Colo-rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Anlotinib plus Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride with Irinotecan</intervention_name>
    <description>Dose escalation of anlotinib starts from 8mg qd d1-14/q21d in combination with fixed dose of irinotecan at 180mg/m2 d1/q14d.</description>
    <arm_group_label>Anlotinib plus Irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria to be eligible for enrollment&#xD;
        into the study:&#xD;
&#xD;
          -  willing and able to provide written informed consent and comply with the requirements&#xD;
             of the study&#xD;
&#xD;
          -  histologically- or cytologically-confirmed advanced colorectal cancer&#xD;
&#xD;
          -  failed or intolerable to at least one prior therapy&#xD;
&#xD;
          -  have evidence of measurable disease per RECIST v1.1&#xD;
&#xD;
          -  Eastern Collaborative Oncology Group (ECOG) Performance Status ≤ 1&#xD;
&#xD;
          -  weight ≥40kg&#xD;
&#xD;
          -  life expectancy &gt;12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting any of the following criteria are ineligible for participation in the&#xD;
        study:&#xD;
&#xD;
          -  history of any anti-cancer therapy (including investigational agents) within 28 days&#xD;
             prior to study entry&#xD;
&#xD;
          -  presence of toxicity of prior anti-cancer therapy that has not resolved to Grade 1, as&#xD;
             determined by National Cancer Institute's Common Terminology Criteria for Adverse&#xD;
             Events (NCI-CTCAE) Version 4.03&#xD;
&#xD;
          -  symptomatic brain metastasis requiring active treatment&#xD;
&#xD;
          -  any previous malignancy, except for non squamous-cell carcinoma of skin or&#xD;
             carcinoma-in-situ of the uterine cervix within 5 years prior to study entry&#xD;
&#xD;
          -  active or clinically unstable infection requiring systemic therapy&#xD;
&#xD;
          -  unable to swallow oral medications or with gastrointestinal disorders that might&#xD;
             interfere with proper absorption of oral drugs&#xD;
&#xD;
          -  active digestive ulcer disease, inflammatory bowel disease, intestinal obstruction or&#xD;
             any other condition that, in the clinical judgment of the Principal Investigator, may&#xD;
             cause severe gastrointestinal bleeding or perforation&#xD;
&#xD;
          -  unstable pulmonary embolism, deep vein thrombosis, or other significant&#xD;
             arterial/venous thromboembolic event ≤2 months prior to study entry&#xD;
&#xD;
          -  history of stroke or transient ischemic attack (TIA) within 12 months prior to study&#xD;
             entry&#xD;
&#xD;
          -  any of the following abnormal findings in organ or marrow function 1 week prior to&#xD;
             study entry:&#xD;
&#xD;
               -  Leukocytes &lt; 1.5*10^9/L, or Platelets &lt; 100*10^9/L, or Hb&lt; 90g/L&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5 × institutional upper limit of normal (ULN), or AST&#xD;
                  (aspartate amino transferase)/ALT (alanine amino transferase)&gt; 3 × institutional&#xD;
                  ULN for liver metastases, &gt; 1.5 × institutional ULN in case of no liver&#xD;
                  metastases&#xD;
&#xD;
               -  any electrolyte imbalance of clinical significance&#xD;
&#xD;
               -  creatinine &gt; institutional ULN and creatinine clearance &lt; 60 mL/min&#xD;
&#xD;
               -  spot urine protein ≥(2+) or 24-hour proteinuria ≥1.0g/24h&#xD;
&#xD;
               -  APTT (activated partial thromboplastin time) or INR (international normalized&#xD;
                  ratio for prothrombin time) &gt; 1.5 × institutional ULN&#xD;
&#xD;
          -  treatment refractory hypertension defined as a blood pressure of systolic&gt; 140&#xD;
             millimeter of mercury (mm Hg) and/or diastolic &gt; 90 mm Hg which cannot be controlled&#xD;
             by a single anti-hypertensive agent&#xD;
&#xD;
          -  LVEF (left ventricular ejection fraction ) &lt;50%&#xD;
&#xD;
          -  history of acute coronary syndromes (including myocardial infarction and unstable&#xD;
             angina), coronary artery bypass graft within 6 months prior to study entry, or history&#xD;
             or evidence of current ≥ Class II congestive heart failure as defined by New York&#xD;
             Heart Association (NYHA)&#xD;
&#xD;
          -  present with non-healing fractures of bone or wounds of skin&#xD;
&#xD;
          -  pregnant or lactating female&#xD;
&#xD;
          -  sexually active female (of childbearing potential) or male unwilling to adopt an&#xD;
             effective method of birth control during the course of the study&#xD;
&#xD;
          -  serious and/or unstable pre-existing psychiatric disorder&#xD;
&#xD;
          -  familial, sociological or geographical conditions that, in the clinical judgment of&#xD;
             the Principal Investigator, do not permit compliance with the protocol&#xD;
&#xD;
          -  known immediate or delayed hypersensitivity reaction to anlotinib, irinotecan or their&#xD;
             excipients&#xD;
&#xD;
          -  administration of irinotecan in prior treatments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital,CAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Huang, MD</last_name>
    <phone>86-10-87788102</phone>
    <email>huangjingwg@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan Song, M.D</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jing Huang</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Huang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>August 3, 2018</last_update_submitted>
  <last_update_submitted_qc>August 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jing Huang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

